Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Bipodal-Peptide Binder
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Peptide molecules to specifically bind targets such as aptamer, avimer and kunitz domain have been intensively studied and developed as alternatives to antibodies....
Contact Yong U Kim
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Unique Structural Scaffold , High Affinity to Target Moleuces, Small Molecular Weight , Economic Production , Versatile Application

The core technology of Gwangju Institute of Science and Technology (GIST) is to provide novel peptide molecules named as bipodal peptide binder (BPB). The BPB molecule having unique structural scaffold exhibits high affinity and specificity to target molecules.


Background and unmet needs: Peptide molecules to spcifically bind targets such as aptamer, avimer and kunitz domain have been intensively studied and developed as alternatives to antibodies. The peptides with high affinity to targets can be used as drugs or diagnositic agents, particulary where whole antibodies may be unsuitable. Given applibility and market potential of peptide molecules as drugs or diagnositic agents, a multitue of companies and laboratories are researching to seek peptide molecules with a novel structure.


Discovery and Achievements:  The bipodal peptide binder (BPB) of the GIST has a novel and unique structure comprising one structure stabilizing region and two target binding regions. The structure stabilizing region plays a crucial role in forming the structure of the BPB and two target binding regions cooperatively bind to two different regions of a target molecule. The biding affintiy of the BPB is determined by two target binding regions as well as the structure stabilizing region and the specificity by two target binding regions. The amino acid sequence of the target binding region can be randomly changed by a phage display technology to increase the affinity.


Key Features and Advantages:


                     (a) Unique structural scaffold


The bipodal peptide binder (BPB) has a novel and unique structural scaffold with one structure stabilizing region and two target binding regions to provide high affinity and specificity to target molecules.


(b) High Affinity to Target Moleuces


The BPB molecule has nM affinity to target molecules, even though its molecular weight is much smaller than whole antibody molecules. This high affinity highlights applications of the BPB molecule to drugs and diagnostic agents.


(c) Small Molecular Weight


The BPB molecules can be constructed using only 20-30 amino acids (2.2-4 kDa). Such small molecular weights permit to overcome shortcomings of antibodies having large molecular weights.


(d)   Economic Production


The BPB molecules having smaller molecular weights can be produced in cost-effective manners. For example, they can be chemically synthesized in conventional peptide synthesis processes.


(e)   Versatile Application


The BPB molecules can be developed as drugs and diagnostic agents (in vivo and ex vivo imaging) because they can bind to target molecules with high affinity and specificity.


 


 

FEATURED
Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE